Cite

    Kobayashi, H. et al. (2022). Differential prognostic impact of complete blood count-related parameters by prior use of novel androgen receptor pathway inhibitors in docetaxel-treated castration-resistant prostate cancer patients. Anti-cancer drugs. 33 (1), p. . [Online].